

1 Congenital disorder of glycosylation caused by starting site-specific variant in syntaxin-5

2

3 Peter T.A. Linders¹, Eveline C.F. Gerretsen¹, Angel Ashikov^{2,3}, Mari-Anne Vals^{4,5}, Natalia H. Revelo¹, Richard
4 Arts¹, Melissa Baerenfaenger², Fokje Zijlstra³, Karin Huijben³, Kimiyo Raymond⁶, Kai Muru^{5,7}, Olga Fjodorova⁷,
5 Sander Pajusalu^{5,7}, Katrin Õunap^{5,7}, Martin ter Beest¹, Dirk Lefeber^{2,3,*} and Geert van den Bogaart^{1,8,*}

6

7 ¹ Department of Tumor Immunology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands

8 ² Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical
9 Center, 6525 GA, Nijmegen, The Netherlands

10 ³ Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical
11 Center, 6525 GA, Nijmegen, The Netherlands

12 ⁴ Children's Clinic, Tartu University Hospital, Estonia

13 ⁵ Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Estonia

14 ⁶ Department of Laboratory Medicine and Pathology, Mayo College of Medicine, Rochester, Minnesota, USA.

15 ⁷ Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia

16 ⁸ Department of Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology Institute,
17 University of Groningen, 9747AG, Groningen, Netherlands

18 * Correspondence: dirk.lefeber@radboudumc.nl; Tel.: +31-24-36-14567; g.van.den.bogaart@rug.nl; Tel.: +31-
19 50-36-35230

20

21 Abstract

22 The SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) protein syntaxin-5 (Stx5)
23 is essential for Golgi transport. In humans, the *STX5* mRNA encodes two protein isoforms, Stx5 Long (Stx5L)
24 from the first starting methionine and Stx5 Short (Stx5S) from an alternative starting methionine at position
25 55. In this study, we identified a novel human disorder caused by a single missense substitution in the second
26 starting methionine (p.M55V), resulting in complete loss of the short isoform. Patients suffer from an early
27 fatal multisystem disease, including severe liver disease, skeletal abnormalities and abnormal glycosylation.

28 Whereas Golgi morphology was unaltered, primary human dermal fibroblasts isolated from these patients

29 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**
showed defective glycosylation and mislocalization of glycosyltransferases. Measurements of anterograde

30 trafficking, based on biotin-synchronizable forms of Stx5 (the RUSH system), and of cognate binding SNAREs,
31 based on Förster resonance energy transfer (FRET), revealed that the short isoform of Stx5 is essential for
32 intra-Golgi transport. This is the first time a mutation in an alternative starting codon is linked to human
33 disease, demonstrating that the site of translation initiation is an important new layer of regulating protein
34 trafficking.

35 **Keywords**

36 Syntaxin-5, ER-Golgi trafficking, glycosylation, secretory pathway, congenital disorders of glycosylation

37

38 Introduction

39 In eukaryotes, proteins destined for the secretory pathway are synthesized at the endoplasmic reticulum (ER)
40 and then transported to the Golgi apparatus, where they are sorted for their ultimate destinations at the
41 *trans*-Golgi network. Central to this process is intracellular membrane fusion, which is mediated by members
42 of the SNARE (soluble *N*-ethylmaleimide-sensitive factor attachment protein receptor) protein family.
43 Membrane fusion is the result of the formation of a tight alpha-helical coiled-coil bundle by cognate SNARE
44 proteins that are present in both the carrier vesicle and target membranes. Membrane fusion requires an R-
45 SNARE, characterized by an arginine residue located central in the SNARE bundle, and three Q-SNAREs, with
46 glutamine residues instead. For anterograde ER to Golgi trafficking, the target (t-) SNARE complex is formed by
47 the Qa-SNARE syntaxin-5 (Stx5)¹⁻⁴, together with the Qb-SNAREs GosR1 (also known as GS27 or membrin) or
48 GosR2 (GS28), and R-SNAREs Ykt6 or Sec22b (Ers24)⁵⁻⁷. Generally in mammalian cells, the R-SNAREs act as
49 vesicle (v-) SNAREs and the Q-SNAREs together form the t-SNARE complex on the target membrane⁸. In
50 contrast, the Qc-SNAREs Bet1 and Bet1L (GS15) function as the v-SNAREs at the ER/Golgi interface⁹⁻¹². This
51 possibly prevents the formation of non-functional SNARE complexes during ER to Golgi transit. In addition,
52 Stx5 functions in retrograde intra-Golgi transport by forming a SNARE complex with GosR1, Bet1L, and Ykt6^{12,13}
53 and in retrograde trafficking from endosomes to the *trans*-Golgi network (TGN)^{14,15}, making it a unique SNARE
54 protein involved in both anterograde and retrograde Golgi transport.
55 *STX5* is highly conserved and is an essential gene in animals and fungi^{16,17}. In animals, Stx5 exists as a long and
56 a short isoform translated from the same mRNA: 39.6 kDa sized Stx5 Long (Stx5L) and 34.1 kDa sized Stx5
57 Short (Stx5S)^{13,18}. This is in contrast to lower organisms such as *Saccharomyces cerevisiae*, which only
58 expresses a single isoform of Stx5 (Sed5p), likely resembling mammalian Stx5L with the presence of an N-
59 terminal COPI-binding tribasic motif¹⁹. The emergence of a second Stx5 isoform can be traced back to the
60 pacific purple sea urchin, *Strongylocentrotus purpuratus*, and is also present in the model organism *Danio*
61 *rerio*, but not in *Drosophila melanogaster* or *Caenorhabditis elegans*. Compared to Stx5S, Stx5L contains 54
62 extra N-terminal residues bearing an Arginine – Lysine – Arginine (RKR) ER retrieval motif, and as a result, Stx5L
63 locates more to the ER whereas Stx5S locates more to the Golgi network^{13,18,20-22}. The evolutionary necessity of
64 Stx5L remains unclear but it has been suggested that Stx5L is important to maintain ER structure by binding
65 microtubules, possibly via CLIMP-63^{21,23}. In addition, immunoprecipitations showed that GosR1 and Bet1L
66 preferentially interact with Stx5S over Stx5L^{24,25}, suggesting that Stx5S might act in more fusogenic complexes

67 later at the ER-Golgi interface whereas Stx5L might be more involved in earlier fusion steps. In the present
68 study, we identified a genetic variant in the second translation codon methionine-55, fully abrogating the
69 production of Stx5S and providing a unique opportunity to study the physiological relevance of the existence
70 of two isoforms in humans. Patients homozygous for this mutation have a very severe clinical phenotype
71 associated with infantile mortality and defective protein glycosylation. We demonstrate that although Stx5L
72 can largely compensate for the lack of Stx5S, the loss of Stx5S leads to defects in anterograde Golgi trafficking
73 with mislocalization of glycosyltransferases, which results in pronounced defects in glycosylation. Moreover,
74 by synchronizing the intracellular trafficking of Stx5 isoforms, we reveal differential trafficking routes for either
75 isoform and identify Stx5S as the dominant Qa-SNARE for intra-Golgi transport. This is the first time that a
76 mutation in an alternate starting site of ribosomal translation is related to human disease. This finding reveals
77 that protein function can be regulated at the level of translation initiation and has profound effects on
78 intracellular membrane trafficking and Golgi function.

79

80 **Results**

81 *Clinical data*

82 The family history ([Supplementary Figure 1](#)) revealed multiple deceased individuals (IV:3, IV:9, IV:10) shortly
83 after birth, spontaneous abortions (IV:5, IV:6, IV:7), and elective abortions in the 20th-21st week of pregnancy
84 due to abnormal fetal ultrasound (US) (IV:4, IV:8). Fetal US of individuals IV:8, IV:9, and IV:10 ([Figure 1a-c](#),
85 [respectively](#)) showed shortening of the long bones with suspicion of chondrodysplasia. Patients IV:9 and IV:10
86 showed highly dysmorphic facial features (high forehead, frontal bossing, prominent glabella, short and
87 upturned nose, long philtrum, micrognathia and dysplastic ears), skeletal dysplasia (short extremities and
88 narrow thorax), profound hypotonia, hepatomegaly, and many abnormal laboratory parameters including
89 elevated cholesterol ([Figure 1b, c](#), [Supplementary Table 1](#)). After birth, the main clinical problem for both
90 patients IV:9 and IV:10 was progressive liver failure with cholestasis and hyperinsulinemic hypoglycemia
91 ([Supplementary Table 1](#)). Liver failure was the main cause of death at the age of 28 days and 8 months, in
92 patients IV:9 and IV:10, respectively. Autopsy of fetus IV:8 revealed bilateral hydronephrosis and sacral
93 lordosis. Autopsy of patient IV:9 showed hepatomegaly with stage 3 to 4 liver fibrosis, agenesis of left kidney,
94 hyperemia of internal organs, ventricular septal defect and suggestive pathohistological features of

95 chondrodysplasia. Autopsy of patient IV:10 showed biliary cirrhosis and nodular regenerative hyperplasia,
96 pancreatic hypertrophia/hyperplasia, and narrow thorax with normal lung development.

97

98 ***Abnormal protein glycosylation suggests a defect in Golgi trafficking***

99 Known genetic causes for skeletal dysplasias were excluded (IV:8), no submicroscopic chromosomal
100 abnormalities were found, while most metabolic investigations were normal except for the Congenital
101 Disorders of Glycosylation (CDG) (IV:9 and IV:10). CDG screening revealed a strong hyposialylation of protein
102 N-glycosylation and mucin-type O-glycosylation, as analyzed by isofocusing of respectively plasma transferrin
103 (Fig 1d) and apolipoprotein CIII (ApoCIII-IEF, Fig 1e). ApoCIII-IEF showed a strong increase of non-sialylated
104 apoCIII (ApoCIII-0), even stronger than observed for genetic defects in the Conserved Oligomeric Golgi (COG)
105 complex, a known group of disorders with disturbed Golgi homeostasis and abnormal glycosylation. To gain
106 more insight into the abnormal N-glycan structures, mass spectrometry was performed of intact transferrin
107 (Fig 1f, g, Supplementary Figure 2) and of total plasma protein derived N-glycans (Fig 1f, h, Supplementary
108 Figure 3). Analysis of intact transferrin of individuals IV:9 and IV:10 revealed multiple abnormal glycan
109 structures, divided into two categories: high mannose structures and truncated glycans. A dominant
110 accumulation was found of high-mannose glycans (Supplementary Table 2, Man5, mass/peak number)
111 suggesting a problem with MGAT1, the enzyme that adds the next *N*-acetylglucosamine during *N*-
112 glycosylation. Furthermore, a series of transferrin isoforms was observed with reduced incorporation of
113 galactose and sialic acid residues. Analysis of N-glycans released from total plasma proteins recapitulated the
114 two categories of abnormal glycans with the accumulation of high mannose glycans, as well as reduced
115 incorporation of galactose and sialic acid residues (Supplementary Table 3).
116 Together, these data indicate that the activities of multiple glycosyltransferases in the Golgi apparatus are
117 affected, covering both *N*- and *O*-glycosylation, thereby suggesting a general disturbance in Golgi trafficking.

118

119 ***Molecular investigations result in the identification of variants in STX5***

120 Chromosomal microarray analysis (CMA) using HumanCytoSNP-12 microarrays revealed multiple long
121 contiguous stretches of homozygosity (LCSH, >5 Mb) distributed across the entire genome, with several
122 regions of homozygosity on chromosome 11 in all three affected sibs (IV:8, IV:9 and IV:10, Supplementary
123 Table 4). Exome sequencing was performed in proband IV:9 to find the genetic variant that could be associated

124 with the disease. Only two homozygous rare protein-altering variants without homozygous individuals in the
125 gnomAD v3 database were identified in shared homozygous stretches on chromosome 11. First, a missense
126 variant in the *VPS37C* gene was discovered (NM_017966.4:c.760G>T p.(Gly254Cys) rs201088253). However, as
127 this variant reaches an allele frequency of 0.9% in Estonia, it is unlikely to cause a rare genetic disorder. The
128 second variant was identified in the *STX5* gene (NM_003164.4:c.163A>G p.(Met55Val), Fig 2a). This is a
129 missense mutation affecting the alternative starting codon for the production of the short Stx5 isoform. The
130 variant is absent from the gnomAD v3 database and was thus classified as a potentially disease-causing
131 variant. The variant was confirmed by Sanger sequencing as homozygous in all affected individuals (IV:8, IV:9,
132 and IV:10) and as heterozygous in the mother (III:2). Paternal DNA was not available for testing.
133 To confirm the effect of the genetic variant on both Stx5 proteoforms, immunoblotting was performed in
134 primary dermal fibroblasts of patients IV:9 and IV:10. While Stx5L was present, a total absence of Stx5S was
135 found in both patient fibroblasts (Fig. 2b, c). We next tested the expression of known interaction partners of
136 Stx5. The levels of Qc-SNARE Bet1L (Fig. 2b, c), which forms a complex with Stx5 upon retrograde intra-Golgi
137 trafficking¹²⁻¹⁵, were also reduced. In contrast, the expression of Qc-SNARE Bet1, which forms a complex with
138 Stx5 upon anterograde ER-Golgi trafficking^{5,7,13,26} was not reduced (Fig. 2b, c). Likewise, the expression of Qb-
139 SNAREs GosR1 and GosR2, which can complex with Stx5 for anterograde ER-Golgi trafficking and retrograde
140 intra-Golgi trafficking^{4,5,7,12,13,24} were unaltered in patient dermal fibroblast lysates. We hypothesized that a
141 compensatory mechanism might exist by upregulating the expression of the *trans*-Golgi Qa-SNARE Stx16²⁷,
142 usually involved in endosome-to-TGN trafficking²⁸, but we did not detect a change of Stx16 expression in
143 patient fibroblast lysates (Fig. 2b, c). As a first step to confirm that fibroblasts offer a useful model to
144 recapitulate the cell biological abnormalities due to loss of the Stx5S isoform, we studied glycosylation by
145 fluorescently-labeled lectins.

146

147 ***Glycosylation defects in Stx5M55V patient fibroblasts***

148 Cell surface staining with the lectin SNA-I from *Sambucus nigra*, which binds terminal sialic acid in an α -2,6
149 linkage of fully-formed N-glycan moieties and, to a lesser extent, sialic acid in an α -2,3 linkage, showed that
150 glycosylation was also impaired at the cellular level in patient fibroblasts. Compared to fibroblasts of healthy
151 donors, we observed a more than two-fold reduced SNA-I labeling intensity in Stx5M55V patient fibroblasts
152 (Fig. 2d,e). To confirm this glycosylation defect, we performed cell surface staining with the lectin PNA (Peanut

153 agglutinin) from *Arachis hypogaea*, which binds terminal galactose residues present on mucin O-glycan
154 moieties. Opposite to our findings with SNA-I, we observed an increased labeling intensity in Stx5M55V patient
155 fibroblasts relative to healthy control by about eight-fold (Fig. 2f,g). As these results reiterate the glycosylation
156 defect observed on serum transferrin, total plasma N-glycans and apoCIII mucin O-glycans, using patient
157 fibroblasts is a suitable model to investigate the cell biological consequences of the complete disruption of the
158 Stx5S isoform.

159

160 ***Stx5M55V mutation results in mislocalization of glycosyltransferases***

161 Given that Stx5 mediates ER-Golgi trafficking^{2,4-7,12,13,15,24,26}, we next investigated whether the glycosylation
162 defect in Stx5M55V patient fibroblasts was caused by the mislocalization of glycosyltransferases. We
163 performed immunofluorescence labeling of mannosyl (α -1,3-)-glycoprotein β -1,2-*N*-
164 acetylglucosaminyltransferase (MGAT1, also known as GnTI), which catalyzes the addition of GlcNAc to the
165 immature man-5 N-glycan. Compared to healthy donor fibroblasts, MGAT1 colocalizes only slightly less with
166 the *cis*-Golgi marker GM130 in patient fibroblasts (Supplementary Fig. 4a, b), but colocalized substantially less
167 with the *trans*-Golgi network marker TGN46 (Fig. 3a, b). In contrast, alpha-mannosidase 2 (MAN2A1), which
168 catalyzes the final hydrolytic step in the N-glycan maturation pathway after MGAT1 conversion, colocalized
169 substantially less with both GM130 (Fig. 3c, d) and TGN46 (Supplementary Fig. 4c, d). Similarly to MGAT1,
170 beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1), which catalyzes the transfer of sialic acid to galactose
171 residues of N-glycans in an α -2,6 linkage, colocalized less with both GM130 (Supplementary Fig. 4e, f) and
172 TGN46 (Supplementary Fig. 4g, h). Finally, *N*-acetylgalactosaminyltransferase 2 (GALNT2), which catalyzes the
173 initial reaction in mucin O-linked glycan synthesis, localized more to the *cis*-Golgi (marker Zinc finger protein-
174 like 1 (ZFPL1)²⁹) (Fig. 3e, f) and less to the *trans*-Golgi (Fig. 3g, h).

175 Taken together, the loss of Stx5S results in irregular localization of glycosyltransferases to the Golgi apparatus.
176 Mislocalization of glycosyltransferases can have a profound impact on glycosylation as shown by
177 computational simulations³⁰. Notwithstanding these large defects in glycosylation in the Stx5M55V patients,
178 negative staining electron microscopy and immunofluorescence labeling of *cis*- and *trans*-Golgi markers
179 showed no large alterations in Golgi morphology and the polarized arrangement of Golgi apparatus cisternae
180 was still present in Stx5M55V fibroblasts (Supplementary Figure 5). These results indicate that although Stx5L

181 is sufficient to maintain normal Golgi apparatus morphology, Stx5S is required for proper trafficking of
182 glycosylation enzymes.

183

184 ***Stx5 mediates retrograde Golgi trafficking***

185 As Stx5 is required for trafficking of glycosylation enzymes, we then studied the role of the two Stx5 isoforms
186 in ER-Golgi trafficking. Because Stx5L contains an RKR ER-retrieval motif in its N-terminal extension, it locates
187 more at the ER compared to Stx5S^{13,18,20,21}. In line with this, we observed a more dominant localization of Stx5L
188 at the ER and less at various Golgi compartments in Stx5M55V fibroblasts compared to total Stx5 localization
189 in healthy control fibroblasts (Fig. 4a, b, d, e, Supplementary Fig. 6a, b, d, e). A notable difference was the far
190 more diffuse staining in Stx5M55V patients of the COPI coat protein β COP (Fig. 4a, c) and of TGN46 (Fig. 4d, f).
191 In contrast, we observed a small increase in GM130 fluorescence in Stx5M55V patients (Supplementary Fig.
192 6f). Western blot showed that total cellular levels of β COP and GM130 were not altered in Stx5M55V patients
193 (Fig. 4g). In contrast, total TGN46 protein levels were reduced in patient fibroblasts (Fig. 4h). These findings
194 suggest that loss of Stx5S results in reduced COPI trafficking between GM130-marked *cis*- and TGN46-marked
195 *trans*-Golgi compartments. As COPI is also involved in retrograde Golgi-ER transport³¹, we investigated
196 whether trafficking at this interface is compromised in Stx5M55V fibroblasts by using the fungal metabolite
197 Brefeldin A (BFA), which inhibits COPI vesicle formation³². If loss of Stx5S results in reduced retrograde Golgi-
198 ER transport, we expect reduced relocalization of Golgi-resident proteins to ER upon BFA treatment. Indeed,
199 redistribution of GALNT2 from the Golgi to the ER was incomplete in patient fibroblasts (Fig. 5a, b), showing a
200 role for Stx5S in retrograde COPI trafficking. To delineate the role of Stx5L in this process, we generated two
201 clonal HeLa cell lines lacking Stx5L by CRISPR/Cas9 (Stx5 Δ L: B1A7 and C1F4). In these cells, BFA resulted in
202 faster relocalization of GALNT2 to the ER compared to parental HeLa (Fig. 5c, d), indicating that Stx5S suffices
203 for retrograde COPI trafficking and the expression of Stx5L is rate-limiting for this process. Further
204 investigation of anterograde trafficking in Stx5 Δ L cells with H-89 washout (Supplementary fig. 7a, b), the RUSH
205 system for synchronized ER-Golgi transport³³ (Supplementary fig. 7c, d, Supplementary movies 1, 2) and
206 temperature-synchronizable VSVG³⁴ (Supplementary fig. 7e, f, Supplementary movies 3, 4) revealed no
207 phenotype relating to the loss of Stx5L. Thus, these data suggest Stx5L has no necessary function in ER-Golgi
208 trafficking as Stx5S can compensate, while Stx5L can only partly compensate for the loss of Stx5S.

209 ***Discerning the roles of Stx5 isoforms in ER and Golgi trafficking***

210 Our results in patient fibroblasts indicate a differential trafficking role of the two Stx5 isoforms in anterograde
211 ER to Golgi trafficking. To gain more insight in this process, we fused each Stx5 isoform to streptavidin-binding
212 protein (SBP) and mCitrine (Stx5L-SBP-mCitrine and Stx5S-SBP-mCitrine). Moreover, we generated a mutant
213 form of Stx5L where the RKR ER-retrieval motif was converted to 3x alanine (AAA) (Stx5L Δ ER-SBP-mCitrine)¹⁸,
214 to delineate the role of this motif in ER-Golgi transport. The co-expression of these constructs with ER-
215 localized streptavidin enabled the synchronized release of the Stx5 fusion proteins from the ER using biotin,
216 which is the so-called RUSH system³³ (Fig. 6a). Co-expressing each Stx5 isoform with the Golgi marker Giantin
217 fused to mScarlet³⁵ in wildtype HeLa cells, allowed to visualize the trafficking of Stx5-SBP-mCitrine to the Golgi
218 following the addition of biotin (Fig. 6a, b, Supplementary movies 5-7). All three Stx5 isoforms reached the
219 Golgi with the same rate and achieved maximal Golgi localization after 20 minutes (Fig. 6c). However, the
220 subsequent decrease in Golgi localization, attributed to recycling to the ER or probable degradation of the
221 fusion proteins, was faster for Stx5L-SBP-mCitrine than for than for Stx5S or Stx5L Δ ER (Fig. 6c). Thus, the RKR
222 ER retrieval motif of Stx5L is necessary and sufficient for the attenuated presence of Stx5L at the Golgi,
223 supporting that the main role of Stx5S is COPI trafficking specifically at the Golgi.

224

225 ***The two isoforms of Stx5 differently engage in SNARE complexes***

226 Since interactions of Stx5 with Bet1 and Bet1L mediate anterograde ER-Golgi transport and retrograde intra-
227 Golgi transport, respectively⁹⁻¹², we hypothesized that Stx5S would interact more strongly with Bet1L, whereas
228 Stx5L would interact more strongly with Bet1. We set out to test this hypothesis by performing co-
229 immunoprecipitation with our RUSH Stx5 constructs. However, we were unable to resolve differences in
230 binding to endogenous cognate Qc-SNAREs between the two Stx5 isoforms, either without or with 30 mins
231 biotin (Supplementary Fig. 8a, b). A likely explanation is that interactions might occur *in vitro* during the
232 immunoprecipitation. Therefore, we developed an approach to visualize SNARE complexes based on a
233 combination of the RUSH system³³ and our previously developed Förster resonance energy transfer-
234 fluorescence lifetime imaging microscopy (FRET-FLIM) approach for visualization of SNARE complexes³⁶ (Fig.
235 7a). The FRET-FLIM approach employed Stx5 isoforms C-terminally fused with a donor fluorophore (mCitrine)
236 and Bet1L C-terminally fused with an acceptor fluorophore (mCherry). The formation of a post-fusion SNARE
237 complex results in the close proximity of the donor and an acceptor fluorophore resulting in FRET which can be
238 measured from a decreased donor fluorescence lifetime (τ). Contrary to ratiometric FRET, FRET-FLIM is not

239 dependent on local concentration differences or excitation intensities of the donor and acceptor fluorophores,
240 as τ is an intrinsic property of the fluorophore itself. By combining the FRET-FLIM approach with the RUSH
241 system, we were able to control the spatial localization of Stx5 isoforms and measure interactions specifically
242 at the ER (no biotin) or the Golgi apparatus (20 min after biotin addition). 30 minutes prior to imaging, cells
243 were incubated with cycloheximide in culture medium to make sure background interaction from any ER-
244 localized newly synthesized acceptor construct was mitigated.

245 For the mCitrine donor-only Stx5 constructs, we measured similar lifetimes for both isoforms (Fig. 7c,
246 Supplementary Fig. 9a, Stx5L: 3.02 ns \pm 0.004, Stx5S: 2.99 ns \pm 0.007) prior to biotin addition, while these
247 lifetimes slightly decreased following biotin addition (Fig. 9d, Supplementary Fig. 9a, Stx5L: 2.90 ns \pm 0.006,
248 Stx5S: 2.86 ns \pm 0.011). We attribute this reduced lifetime to the fact that mCitrine is somewhat pH-sensitive³⁷
249 and the pH of the Golgi apparatus is lower than in the ER lumen³⁸. We then co-expressed the Stx5 isoforms
250 with mCherry-tagged Bet1L (Bet1L-mCherry) (Fig. 7a,b). At the ER, thus before the release of Stx5 with biotin,
251 we observed reduced lifetimes for both Stx5S and Stx5L with Bet1L-mCherry, compared to the donor-only
252 controls (Fig. 7b, c, Supplementary fig. 9b, Stx5L: 2.82 ns \pm 0.01, Stx5S: 2.79 \pm 0.01), whereas the lifetimes of
253 Stx5S and Stx5L did not significantly differ from each other. After the release in the presence of biotin, this
254 difference between Stx5L and Stx5S became significant and lifetimes were 2.63 ns (\pm 0.01) for Stx5L while
255 Stx5S dropped to 2.52 ns (\pm 0.03) (Fig. 7b, d, Supplementary fig. 9c). To validate that the observed effect is
256 indeed caused by functional SNARE complex formation, we repeated this experiment with VAMP8 instead of
257 Bet1L as the acceptor R-SNARE. VAMP8 has no role in ER-Golgi membrane fusion but rather associates with
258 the late endosomal/lysosomal compartment^{28,36,39-43}. We only observed minor decreases in fluorescence
259 lifetimes for both Stx5L and Stx5S (Supplementary fig. 9d, e, g, prior to biotin Stx5L: 2.92 ns \pm 0.01, Stx5S: 2.86
260 \pm 0.02, upon biotin addition Supplementary fig. 9d, f, h, Stx5L: 2.82 ns \pm 0.01, Stx5S: 2.76 \pm 0.02). The FLIM
261 results with VAMP8 demonstrate that Stx5S interacts more strongly with Bet1L at the Golgi than Stx5L. Thus,
262 Stx5S is the dominant Qa-SNARE for intra-Golgi trafficking.

263

264 Discussion

265 Since the advent of the genomic age, close to 6000 monogenic disorders have been discovered⁴⁴. While nearly
266 all of these disorders result in a truncated, unstable and/or nonfunctional protein, e.g. due to a genetic variant
267 in the catalytic site or protein misfolding, isoform-specific mutations are rare. Here we present the first known

268 mutation in an alternate site of ribosomal translation leading to human disease, namely the mutation of the
269 second starting methionine of Stx5. This mutation leads to the complete and specific loss of Stx5S. Although
270 STX5 is an essential gene for embryonic development in mice^{16,17}, here we show that in humans the loss of
271 Stx5S still allowed a completed pregnancy. Nevertheless, patients have a very severe clinical pathology
272 characterized by infantile mortality due to liver disease, skeletal abnormalities and protein glycosylation
273 defects. While the exact mechanism for alternative translation is unclear, this might be an actively regulated
274 process. It could also be simply regulated by the affinity of the ribosome for the nucleotide sequence upstream
275 of the starting codon. Supporting the latter option, analysis of translation initiation sites with NetStart⁴⁵
276 revealed that the starting codon of Stx5S is located in a more optimal nucleotide context than the starting
277 codon for Stx5L (Supplementary fig. 10). This could lead to more leaky ribosomal scanning^{46,47}, resulting in a
278 lower expression of Stx5L than Stx5S in controls.

279 Cofractionation and microscopy studies have revealed that the localization of Stx5L and Stx5S overlap to a
280 large extent, but that they are generally distributed as a gradient between ER, ERGIC, and Golgi apparatus²⁰.
281 This observation has previously led to the suggestion that Stx5L might play a role in early Golgi trafficking,
282 while Stx5S functions in late Golgi trafficking^{2,4-7,12,13,15,24,26}. Our data now shows that this is not the case and
283 that both Stx5 isoforms can mediate both early and late anterograde and retrograde trafficking with sufficient
284 fidelity to keep the layered Golgi morphology intact. However, the role of Stx5S is more important for
285 anterograde trafficking, and its absence leads to an altered Golgi distribution of glycosylation enzymes and
286 trafficking proteins. In contrast, loss of Stx5L leads to faster anterograde trafficking suggesting it might be
287 more involved in retrograde trafficking and/or sequestering interactions partners of Stx5S. The dominant role
288 of Stx5S in intra-Golgi trafficking is corroborated by the observation that cellular levels of Bet1L, with known
289 roles in intra-Golgi trafficking, are lower in Stx5M55V patient cells. Interestingly, genetic variants in conserved
290 oligomeric Golgi (COG) tethering complex components, which are also implicated in CDGs, resulted in lower
291 levels of Bet1L as well⁴⁸. Although the Stx5-Bet1L interaction has been reported in several studies^{14,31}, our
292 study now shows this interaction *in situ* using FLIM. This interaction is localization dependent and occurs
293 mostly when Stx5 is localized at the Golgi. Moreover, we observed stronger interaction of Bet1L with Stx5S
294 compared to Stx5L at the Golgi, which is likely the result of the differential localization of both isoforms.

295 An important function of the Golgi apparatus is protein glycosylation⁴⁹. Collectively, somatic mutations
296 affecting glycosylation are classified as CDGs and currently over 100 monogenic diseases affecting

297 glycosylation have been identified^{50,51}. A significant number of these include defects in Golgi trafficking, such
298 as the components of the conserved oligomeric Golgi tethering complex (COG)⁵²⁻⁶⁰, mutations in genes coding
299 for the vacuolar H⁺-ATPase and its assembly factors⁶¹⁻⁶⁴, and novel genes involved in Golgi ion homeostasis⁶⁵⁻
300 ⁶⁷. Furthermore, defects are known in components associated with COPI-coated vesicles⁶⁸ that result in
301 deficient protein glycosylation in patient cells, but are not linked to abnormal glycosylation of proteins in
302 plasma and thus escape routine CDG screening. Our study is the first example of an ER-Golgi SNARE being
303 implicated in CDG, thus highlighting the potential of glycosylation screening in patients to uncover novel cell
304 biological mechanisms.

305 While the cellular effects of the loss of Stx5S in Stx5M55V mutant fibroblasts are subtle, there can be
306 pronounced consequences in secretory cells, such as exocrine and endocrine cells, which are sensitive to
307 minor disruptions of the secretory pathway^{49,68-70}. Recent modeling showed that the slight mislocalization of
308 glycosyltransferases can result in large differences in glycosylation patterns, because glycosylation is the result
309 of the sequential addition and removal of different sugar moieties at the various Golgi compartments³⁰. The
310 defects in intra-Golgi trafficking can explain the other pathologies as well. For instance, Stx5 can participate in
311 the trafficking and processing of the very low-density lipoprotein receptor (VLDL-R) and this role is heavily
312 dependent on the expression of Stx5⁷¹, thus providing an explanation for the observed cholesterol
313 homeostasis defect with elevated cholesterol in all Stx5M55V patients.

314 In summary, we have demonstrated the first known mutation in an alternative starting codon leading to
315 human disease, with severe impact on intracellular membrane trafficking and leading to the discovery of a
316 novel CDG.

317

318 **Acknowledgments**

319 We thank the family for participating in this study. We thank following people for constructs: Hesso Farhan
320 and Franck Perez (Str-KDEL_ManII-SBP-EGFP; Addgene plasmid #65252), Jennifer Lippincott-Schwartz (pEGFP-
321 VSVG; Addgene plasmid #11912) and Feng Zhang (pSpCas9n(BB)-2A-Puro (PX462) V2.0; Addgene plasmid
322 #62987). We also thank the Microscopic Imaging Center of the Radboud Institute for Molecular Life Sciences
323 for use of their microscopy facilities. N.H.R. is funded by a Long-Term Fellowship from the European Molecular
324 Biology Organization (EMBO-LTF, ALTF 232-2016) and a Veni grant from the Netherlands Organization for
325 Scientific Research (016.VENI.171.097). G.v.d.B. is funded by a Young Investigator Grant from the Human

326 Frontier Science Program (HFSP; RGY0080/2018) and a Vidi grant from the Netherlands Organisation for
327 Scientific Research (NWO-ALW VIDI 864.14.001). D.J.L. is funded by a Vidi grant (ZONMW VIDI 917.13.359), a
328 ZONMW Medium Investment Grant (40-00506-98-9001) from the Netherlands Organisation for Scientific
329 Research, and Erare grants EUROCDG2 and Euroglycanomics. K.Õ, M.-A.V., S.P., and K.M. were supported by
330 the Estonian Research Council grants GARLA8175, PUT355, PUTJD827 and PRG471.

331

332 **Author Contributions**

333 P.T.A.L., M.t.B., D.J.L., and G.v.d.B. designed the experiments and wrote the paper. E.C.F.G. contributed to the
334 Stx5 kinetics, co-immunoprecipitation, and FLIM experiments. A.A., M.-A.V., M.B., F.Z., K.H., K.R., K.M., and
335 K.Õ. contributed to the clinical data, exome sequencing and glycomics. O.F. and S.P. performed homozygosity
336 mapping and prioritization of exome variants. N.H.R. performed TEM. R.A. contributed to the Stx5ΔL
337 experiments. P.T.A.L. and M.t.B. performed all other experiments. All authors contributed to writing the
338 manuscript.

339

340 **Declaration of Interests**

341 The authors declare that they have no competing financial interests.

342

343 **Methods**

344 *Ethics*

345 The study was approved by Research Ethics Committee of the University of Tartu (approval dates 19.12.2011,
346 20.02.2012 and 17.03.2014, and approval numbers 210/M-17, 212/M-31 and 235/M-13, 17.03.2014,
347 respectively) and were strictly in accordance with the Declaration of Helsinki. Informed consent for carrying
348 out research was obtained from the family of investigated individuals.

349

350 *Glycosylation studies*

351 Screening for Congenital Disorders of Glycosylation (CDG) was carried out as described before⁶². Plasma N-
352 glycan profiling was performed by MALDI-TOF mass spectrometry of permethylated glycans⁷², using 10 µL of
353 plasma. High resolution mass spectrometry of intact transferrin was performed on a 6540 nanochip QTOF
354 (Agilent), according to published protocols⁷³.

355

356 *Microarray analysis*

357 DNA was extracted either from peripheral blood according to the standard salting out protocol (IV:9 and IV-
358 :10) or from amniotic fluid cell culture (IV:8). Screening for chromosomal abnormalities was performed using
359 HumanCytoSNP-12 BeadChips (Illumina Inc., San Diego, CA, USA). 200 ng of total DNA per sample was
360 processed according to the protocol supplied by the manufacturer. Genotypes were called by GenomeStudio
361 v2011.1 software and the data were analyzed using GenomeStudio Genome Viewer tool (Illumina Inc.). The
362 minimum threshold for LCSH (long contiguous stretches of homozygosity) regions was set at 5 Mb.

363

364 *Exome sequencing*

365 Genomic DNA was extracted from fibroblasts from patient IV:9 according to the manufacturer's protocol using
366 a Qiagen Mini Kit (Qiagen) and was checked for DNA degradation on agarose gels. Next generation sequencing
367 (NGS) and analysis was performed as described⁶³. In brief, exome enrichment was performed using the
368 SureSelect Human All Exon 50 Mb Kit (Agilent), covering ~21,000 genes. The exome library was sequenced on a
369 SOLiD 5500xl sequencer (Life Technologies). Color space reads were iteratively mapped to the hg19 reference
370 genome with the SOLiD LifeScope software version 2.1. Called variants and indels were annotated using an in-
371 house annotation pipeline^{74,75} and common variants were filtered out based on a frequency of >0.5 % in
372 dbSNP and a frequency of >0.3 % in our in-house database of >5,000 exomes. Quality criteria were applied to
373 filter out variants with less than 5 variant reads and less than 20 % variation. Furthermore, synonymous
374 variants, deep intronic, intergenic and UTR variants were excluded. The identified variant was confirmed by
375 Sanger sequencing in all affected individuals (IV:8, IV:9, and IV:10) and their mother (III:2). Paternal DNA (III:1)
376 was not available.

377

378 *Cell culture*

379 HeLa cells (authenticated by ATCC through their human STR profiling cell authentication service), including
380 Stx5ΔL cell lines, were maintained in high glucose DMEM with Glutamax (Gibco 31966021). Human primary
381 dermal fibroblasts were obtained from patients or healthy donors and maintained in Medium 199 with EBSS
382 and L-glutamine (Lonza BE12-119F). All media were supplemented with 10% fetal calf serum (FCS, Greiner Bio-

383 one, Kremsmünster, Austria) and antibiotic-antimycotic solution (Gibco 15240-062). All cells were regularly
384 tested for mycoplasma contamination.

385

386 *Plasmids and transfection*

387 Str-KDEL_ManII-SBP-EGFP was a gift from Franck Perez (Addgene plasmid #65252;
388 <http://n2t.net/addgene:65252>; RRID:Addgene_65252). VAMP8-mCherry was constructed earlier³⁶ and
389 previously deposited to Addgene (Addgene plasmid #92424). Str-KDEL_Stx5L-SBP-mCitrine and Str-
390 KDEL_Stx5S-SBP-mCitrine were constructed by replacing the ManII-SBP-EGFP cassette in Str-KDEL_ManII-SBP-
391 EGFP using the *Ascl* and *XbaI* restriction sites. Stx5 coding sequences were codon-optimized for *Homo sapiens*
392 using JCat and ordered from Genscript. Stx5L Δ ER coding sequence was generated with Q5-polymerase site-
393 directed mutagenesis, using the Stx5L cDNA as a template with the following primer: 5'- CTTCG AATTC
394 AATGA TTCCG GCCGC CGCCT ACGGC AGCAA GAACA CC. Sequences were verified with Sanger
395 sequencing. HeLa cells were transfected with plasmid vectors using Fugene HD (Promega E2311), using the
396 recommended protocol of the manufacturer. Only cells expressing low to moderate levels of the transfected
397 plasmids, based on fluorescence intensity and manual localization scoring, were chosen for subsequent
398 microscopic analyses.

399

400 *CRISPR/Cas9*

401 Stable knock out of Stx5L in HeLa cells was obtained using the CRISPR-CAS9 method. For this, pairs of gRNA
402 sequences were designed upstream of the STX5 initiation codon (crispr.mit.edu, pair 1: ATAAC CTCGG ACTGT
403 TGTGG AGG and ATGAT CCCGC GGAAA CGCTA CGG; pair 2: TAACC TCGGA CTGTT GTGGA GGG and TGATC
404 CCGCG GAAAC GCTAC GGG). The gRNA sequences were cloned in pSpCas9n(BB)-2A-Puro (PX462) V2.0 (gift
405 from Feng Zhang, Addgene no. 62987)⁷⁶ and transfected into HeLa cells by electroporation (Neon Transfection
406 System, Thermofisher, MA). After initial selection with puromycin, the medium was changed for conditioned
407 medium (collected from wildtype HeLa cells at 70% confluency) supplemented 1:1 with fresh medium. Single
408 clones were obtained and screened for knockout of Stx5L by SDS-PAGE and Western blotting. Two clones
409 (B1A7 and C1F4) were chosen for further experiments.

410

411 *Immunofluorescence*

412 Cells were plated on cleaned 12 mm glass coverslips (Electron Microscopy Services, 72230-01) and the
413 following day fixed with 4% paraformaldehyde for 15 minutes at room temperature. Following quenching with
414 50 mM NH₄Cl in PBS, cells were permeabilized and blocked in 2% normal donkey serum (Rockland, 017-000-
415 121) and 0.1% saponin (permeabilization buffer) for 30 mins at RT. Primary and secondary antibodies (list of
416 antibodies and dilutions in Supplementary Table 5) were diluted in permeabilization buffer and incubated for 1
417 hour at room temperature. Finally, cells were washed with 0.1% Triton X-100 in PBS to remove background
418 staining and mounted with mounting medium containing 0.01% Trolox (6-hydroxy-2,5,7,8-
419 tetramethylchroman-2-carboxylic acid) and 68% glycerol in 200 mM sodium phosphate buffer at pH 7.5 with
420 0.1 µg/ml DAPI. Coverslips were sealed with nail polish. Cells were imaged on a Leica SP8 SMD confocal laser
421 scanning microscope, equipped with an HC PL APO CS2 63x/1.20 WATER objective.

422

423 *Lectin stainings*

424 Cells were plated on cleaned 12 mm glass coverslips and after 72 hours culturing fixed with 4%
425 paraformaldehyde. Cells were blocked with Carbo-Free Blocking solution (Vector Laboratories, SP-5040) and
426 incubated with 4 µg/mL biotinylated SNA-I (Vector Laboratories, B-1305) or PNA (Vector Laboratories, B-1075)
427 diluted in Carbo-Free Blocking solution. Cells were then incubated with Streptavidin-Alexa Fluor 647
428 (ThermoScientific, S32357) before coverslips were mounted as described above. Cells were imaged on a Leica
429 SP8 SMD confocal laser scanning microscope, equipped with an HC PL APO CS2 63x/1.20 WATER objective.

430

431 *Brefeldin A assay*

432 Fibroblasts were plated in black clear-bottom 96-wells plates (Greiner, 655090) and cultured until 80%
433 confluent. Cells were either treated with 10 µg/mL Brefeldin A in DMSO (Cayman Chemicals, 11861) or DMSO
434 alone for 15 minutes in a humidified incubator. After incubation, plates were transferred immediately to ice and
435 cells were fixed with 4% paraformaldehyde, after which the above immunofluorescence protocol was
436 performed. Microscopy images were acquired using a Leica high-content microscopy system based on a Leica
437 DMI6000B (Leica Microsystems) and an HCX PL S-APO 40.0x0.75 DRY objective. HeLa cells were plated on 12
438 mm coverslips and incubated in the same way with Brefeldin A, but fixed with 100% methanol at -20°C for 15
439 mins. Imaging of these samples was performed using a Leica DMI6000B epifluorescence microscope equipped

440 with an HC PL APO 63x1.40 OIL objective. Cells were analyzed using Fiji (<http://fiji.sc/>) by first removing noise
441 outliers (bright outliers, radius 2.0 pixels, threshold 50), then manually selecting cells and measuring the
442 maximum fluorescence intensity in these ROIs. Data were normalized to the mean of the DMSO control of
443 each group.

444

445 *H-89 assay*

446 HeLa cells were plated on 12 mm coverslips and incubated the following day for 30 mins with 100 μ M H-89
447 (Cayman Chemicals, 10010556) in DMSO or DMSO alone (vehicle) and H-89 was washed out with fresh
448 medium for 5 mins. Cells were fixed with 4% paraformaldehyde for 15 mins at RT and permeabilized with
449 100% methanol at -20°C for 15 mins prior to immunostaining with ERGIC53 mouse monoclonal antibody
450 (G1/93 or OTI1A8) before epifluorescence imaging as described for the BFA assay. Cells were analyzed using
451 Fiji and the number of ERGIC53-positive spots was quantified with the Spot Counter plugin. Data were
452 normalized to the mean fluorescence of the DMSO control of each group. Data was analyzed with a Mann-
453 Whitney U non-parametric test.

454

455 *Transmission electron microscopy*

456 Fibroblasts were grown in 12-wells plates and fixed with 2% glutaraldehyde (Sigma-Aldrich, G5882) in PB (0.1
457 M phosphate buffer, pH 7.4) for 60 mins at room temperature. Subsequently, cells were washed four times
458 with PB and post-fixed with 1% osmium tetroxide and 1% potassium ferrocyanide in PB for 60 mins at room
459 temperature. Then, cells were again washed four times with PB and dehydrated with graded steps of ethanol
460 (30%, 50%, 70%, 96%, 100%) and embedded in Epon resin. 70 nm sections were cut with an ultramicrotome,
461 then stained with 2% uranyl acetate solution and lead citrate solution. Stained sections were then examined
462 using a JEOL JEM1400 transmission electron microscope.

463

464 *Live-cell epifluorescence microscopy*

465 Cells were seeded in four-compartment dishes (Greiner 627870) and transfected as described above (3:1
466 weight ratio reporter construct:Golgi label). Briefly before imaging, the culture medium was exchanged for
467 Leibovitz's L-15 (Gibco 21083027). Samples were imaged using a DMI6000B (Leica Microsystems) with a
468 heated stage (Pecon) and objective heater. All samples were imaged using an HC PL APO 63x/1.40–0.60 OIL

469 objective. VSVG-ts045-EGFP experiments were performed at 32°C after overnight incubation at 40°C, while all
470 other epifluorescence experiments were performed at 37°C. For RUSH experiments, an equal amount of
471 Leibovitz's L-15 supplemented with biotin was added to the well immediately before imaging, to reach a final
472 concentration of 40 µM biotin. Live cell imaging was started immediately with 15 sec or 30 sec frame rates.
473 Analysis was performed with Fiji, after registration of the image stacks, the increase in fluorescence was
474 measured in the Golgi area by using the thresholded mScarlet-Giantin signal as an image mask.

475

476 *FRET-FLIM*

477 All imaging took place in Leibovitz's L-15 supplemented with 10 µg/mL cycloheximide (Sigma-Aldrich, C4859)
478 and cells were pulsed with biotin as described above. Imaging was performed on a Leica SP8 SMD system at
479 37°C, equipped with an HC PL APO CS2 63x/1.20 WATER objective. Fluorophores were excited with a pulsed
480 white light laser, operating at 80 MHz. mCitrine was excited at 514 nm, two separate HyD detectors were used
481 to collect photons, set at 521-565 nm and 613-668 nm respectively. Photons were collected for one minute
482 and lifetime histograms of the donor fluorophore were fitted with monoexponential decay functions
483 convoluted with the microscope instrument response function in Leica LAS X.

484 *Immunoprecipitation*

485 HeLa cells were lysed 48 hours post-transfection with IP lysis buffer (20 mM Tris-HCl pH 7.6, 137 mM NaCl, 1%
486 IGEPAL, 2 mM EDTA and complete protease inhibitors (Roche 5892791001)). Protein levels were equilibrated
487 and lysates were immunoprecipitated with 1 µg anti-GFP-antibody (Rockland 600-401-215) and protein A
488 beads (ThermoFisher, 20333) for 1 hour at 4°C with constant agitation. After three washes with IP lysis buffer,
489 samples were boiled in 5x SDS sample buffer with β-mercaptoethanol and resolved with SDS-PAGE and
490 subsequent immunoblotting.

491

492 *SDS-PAGE and immunoblotting*

493 Cells were plated in 12-wells plates in culture medium and lysed the following day with SDS lysis buffer (1%
494 SDS, 10 mM Tris-HCl pH 6.8). Lysates were diluted to equal protein content (30 µg per lane) with SDS lysis
495 buffer, separated with SDS-PAGE on 4–20% Mini-PROTEAN TGX Precast Protein Gels (Biorad, 4561094) and
496 subsequently transferred onto 0.45 µm PVDF membranes. Small molecular weight proteins (Bet1 and Bet1L)
497 were separated on 16% Schaeffer gels⁷⁷.

498

499 *Quantification and statistical analysis*


500 All mean values represent the average of all cells analyzed. All comparisons between two groups were first
501 checked for similar mean and median values and acceptable (< 3x) difference in variance, before statistical
502 analysis with an unpaired two-sided Student's t-test. Relative intensity data was first transformed using the
503 binary logarithm before analysis with an unpaired two-sided Student's t-test. H-89 data was analyzed with a
504 Mann-Whitney U non-parametric test. Stx5 kinetics data were analyzed with a one-way ANOVA, followed by a
505 posthoc Tukey's honestly significant difference test. Stx5 FLIM data were analyzed with a two-way ANOVA,
506 with the isoform and timepoint as independent variables, followed by a posthoc Tukey's honestly significant
507 difference test. $p < 0.05$ was considered significant. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p \leq 0.0001$. All
508 statistical analyses were performed using R statistical software. All numerical data were visualized using R
509 package *ggplot2*⁷⁸, with violins representing the overall distribution of the data and means \pm 95% CI overlaid.

510

511 *Data and code availability*

512 Microarray data, exome sequencing data and ImageJ macros for quantification of the RUSH experiments are
513 available upon request.

514 Figures



515 **Figure 1. A novel, lethal, genetic variant suggests a defect in protein glycosylation related to Golgi**
516 **trafficking.**

517 (a-c) Clinical images of Stx5M55V patients IV:8 (a), IV:9 (b), IV:10 (c).

518 (d) Glycosylation screening by isoelectric focusing (IEF) of serum transferrin. The accompanying numbers
519 represent the total number of sialic acids in the different proteoforms. Both patients show a reduction in the
520 number of sialic acids.

521 (e) Glycosylation screening by IEF of serum Apolipoprotein C3 (ApoCIII). ApoCIII has one mucin-type O-linked
522 glycan with one or two sialic acids in controls. Both patients show a reduction in the number of sialic acids.

523 (f) Schematic overview of N-glycosylation intermediates in the Golgi. For mass spectrometry analysis of glycan
524 structures, glycosylated transferrin is enriched from all secreted glycoproteins in human serum and subjected
525 to intact protein mass spectrometry. In parallel, a different serum sample is treated with PNGase F to cleave
526 and analyze N-glycans from all plasma proteins.


527 (g) Nanochip-C8 QTOF mass spectra of enriched intact serum Transferrin of Stx5M55V patient IV:9 (top
528 spectrum) and healthy control (lower spectrum) are shown. Key transferrin glycoforms are shown, indicating a
529 strong increase of high-mannose glycans and glycans lacking sialic acid and galactose. Annotation of all peaks
530 of patients IV:9 and IV:10 is shown in [Supplementary Table 2](#).

531 (h) MALDI-TOF mass spectra of total plasma N-glycans of Stx5M55V patient IV:9 (top spectrum) and healthy
532 control (lower spectrum) are shown. Structural analysis shows a strong increase of high-mannose glycans and
533 glycans lacking sialic acid and galactose. Annotation of all peaks of patients IV:9 and IV:10 is shown in

534 [Supplementary Table 3](#).

535

536



537

538 **Figure 2. Primary dermal fibroblasts are an accurate model of the glycosylation defect observed in**
539 **Stx5M55V patients.**

540 (a) Schematic representation of the intron-exon structure of *STX5* and the encoded proteoforms resulting from
541 the two starting codons in exon 2. The Stx5M55V genetic variant is indicated by a dashed red line. Orange
542 regions have a secondary helical structure. TMD, transmembrane domain. Ha, Hb, Hc: regulatory Habc-domain

543 (b) Representative immunoblot for SNARE proteins of cell lysates of primary human dermal fibroblasts of
544 healthy donors (green, Ctrl) or Stx5M55V patients (orange, Stx5M55V). α -Tubulin, loading control.


545 (c) Quantification of (b). Protein levels were first normalized to the loading control, then to the average
546 expression of both control lines. Each point represents one cell line from 2 independent experiments.

547 (d) Fibroblasts of healthy donors (green, Ctrl) or Stx5M55V patients (orange, Stx5M55V) were probed with
548 SNA-I lectin (green in merge). Representative confocal micrographs. Scalebars, 25 μ m. DAPI in blue.

549 (e) Quantification of (d). All data were normalized to the healthy donor and then \log_2 -transformed. N = 124
550 (Ctrl) and 111 (Stx5M55V) cells from 2 independent experiments.

551 (f-g) Same as panels (d-e), but now for PNA lectin. N = 117 (Ctrl) and 122 (Stx5M55V) cells from 2 independent
552 experiments.

553



554

555 **Figure 3. Glycosylation enzymes mislocalize in Stx5M55V patient fibroblasts.**

556 (a) Immunofluorescence microscopy of MGAT1 (green in merge) and TGN46 (magenta) in primary dermal
 557 fibroblasts of healthy donors (green, Ctrl) or Stx5M55V patients (orange, Stx5M55V). Representative confocal
 558 micrographs. Scalebars, 10 μ m. DAPI in blue.


559 (b) Pearson's correlations coefficients between MGAT1 and TGN46 of panel (a). N = 157 (Ctrl) and 162
 560 (Stx5M55V) cells from 2 independent experiments.

561 (c-d) Same as panels (a-b), but now for MAN2A1 (green) and GM130 (magenta). N = 127 (Ctrl) and 143
 562 (Stx5M55V) cells from 2 independent experiments.

563 (e-f) Same as panels (a-b), but now for GALNT2 (green) and ZFPL1 (magenta). N = 240 (Ctrl) and 146
 564 (Stx5M55V) cells from 2 independent experiments.

565 (g-h) Same as panels (a-b), but now for GALNT2 (green) and TGN46 (magenta). N = 172 (Ctrl) and 152
 566 (Stx5M55V) cells from 2 independent experiments.


567



568 **Figure 4. Reduced localization of Stx5 to trans-Golgi network in Stx5M55V patients.**

569 (a) Immunofluorescence microscopy of Stx5 (green in merge) and β COP (magenta) in primary dermal
 570 fibroblasts of healthy donors (green, Ctrl) or Stx5M55V patients (orange, Stx5M55V). Representative confocal
 571 micrographs. Scalebars, 10 μ m. DAPI in blue.


- 572 (b) Pearson's correlations coefficients between Stx5 and β COP of panel (a). N = 109 (Ctrl) and 87 (Stx5M55V)
573 cells from 2 independent experiments.
- 574 (c) Fluorescence intensities of β COP from panel (a) relative to the healthy control. N = 109 (Ctrl) and 87
575 (Stx5M55V) cells from 2 independent experiments.
- 576 (d-f) Same as panels (a-c), but now for Stx5 (green) and TGN46 (magenta). N = 128 (Ctrl) and 114 (Stx5M55V)
577 cells from 2 independent experiments for colocalization, N = 822 (Ctrl) and 783 (Stx5M55V) cells from 6
578 independent experiments for intensity.
- 579 (g) Representative immunoblot for GM130 and β COP of the cells from panel A. GAPDH, loading control.
- 580 (h) Same as panel (g), but now for TGN46.
- 581



582 **Figure 5. Loss of Stx5S inhibits ER-Golgi trafficking, while the loss of Stx5L accelerates ER-Golgi trafficking.**

583 (a) Immunofluorescence microscopy of GALNT2 (green in merge) in primary human dermal fibroblasts of
 584 healthy donors (green, Ctrl) or Stx5M55V patients (orange, Stx5M55V) in the absence or presence of Brefeldin
 585 A (BFA) for 15 min. Representative epifluorescence micrographs are shown. Scalebars, 10 μ m. DAPI in blue.
 586 (b) Relative maximum fluorescence intensities of GALNT2 from panel (A). All data were normalized to the
 587 DMSO condition (vehicle). N = 979 (Ctrl) and 943 (Stx5M55V) cells from 2 independent experiments.
 588 (c-d) Same as panels (a-b) B, but now in parental HeLa and Stx5ΔL lines with only 6 min BFA treatment. N = 103
 589 (WT) and 212 (Stx5ΔL) cells from 2 independent experiments.

590




591 **Figure 6. Faster Golgi transit of Stx5L than Stx5S**

592 (a) Schematic overview of the design of Stx5 trafficking experiment, based on the RUSH system. In absence of
 593 biotin (left panel), the reporter cargo (Stx5-SBP-mCitrine) is trapped at the ER by the luminal Str-KDEL hook.

594 When biotin is added (right panel), biotin outcompetes the interaction with streptavidin, allowing Stx5-SBP-
595 mCitrine to traffic freely to its destination compartment. SBP, streptavidin binding protein; Str, streptavidin.
596 (b) Snapshots of live-cell imaging of Stx5-SBP-mCitrine (green in merge). Magenta: Golgi marker Giantin-
597 mScarlet. Scale bars, 10 μ m. See also supplementary movies 5 – 7.

598 (c) Quantification of mCitrine fluorescence at the Golgi of Stx5S-SBP-mCitrine (green), Stx5L-SBP-mCitrine
599 (orange) and Stx5 Δ ER-SBP-mCitrine (blue) over time from panel (b). N = 44 (Stx5S), 47 (Stx5L) and 19
600 (Stx5 Δ ER) cells from 4 independent experiments.

601 (d) Quantification of the slopes from panel (c) of the post-Golgi section (~20 mins onwards).
602



603

604 **Figure 7. Stx5S is the dominant Qa-SNARE for intra-Golgi trafficking**

605 (a) Schematic overview of experimental design for complex formation of Stx5 isoforms with Bet1L, based on
 606 the RUSH system and SNARE complex measurement by FRET-FLIM. In absence of biotin (left panel), the
 607 reporter cargo (Stx5-SBP-mCitrine) is trapped at the ER by the luminal Str-KDEL hook, and no FRET with Golgi-
 608 localized Bet1L-mCherry can occur. When biotin is added (right panel), biotin outcompetes the interaction
 609 with streptavidin, allowing Stx5-SBP-mCitrine to traffic freely to its destination compartment, and SNARE
 610 complex formation with Golgi-localized Bet1L-mCherry can occur resulting in FRET. SBP, streptavidin binding
 611 protein; Str, streptavidin; FRET, Förster resonant energy transfer. FLIM, fluorescence lifetime imaging
 612 microscopy.

613 (b) Representative confocal micrographs of HeLa cells co-expressing Stx5-mCitrine (green in merge) and Bet1L-
 614 mCherry (magenta) without (ER) or with (Golgi) biotin. Scalebars, 10 μ m.

615 (c-d) Average fluorescence lifetimes at the ER (c) and Golgi (d) from panel (b). N = 52 (Stx5S Donor ER), 74

616 (Stx5L Donor ER), 47 (Stx5S Bet1L ER), 51 (Stx5L Bet1L ER), 50 (Stx5S Donor Golgi), 71 (Stx5L Donor Golgi), 58

617 (Stx5S Bet1L Golgi) and 58 (Stx5L Bet1L Golgi) cells from 3 independent experiments. Each point represents
618 one independent experiment.

619 **References**

- 620 1. Bentley, M. *et al.* SNARE status regulates tether recruitment and function in homotypic COPII vesicle
621 fusion. *The Journal of biological chemistry* **281**, 38825–33 (2006).
- 622 2. Dascher, C., Matteson, J. & Balch, W. E. Syntaxin 5 regulates endoplasmic reticulum to Golgi transport.
623 *The Journal of biological chemistry* **269**, 29363–6 (1994).
- 624 3. Rowe, T., Dascher, C., Bannykh, S., Plutner, H. & Balch, W. E. Role of vesicle-associated syntaxin 5 in the
625 assembly of pre-Golgi intermediates. *Science (New York, N.Y.)* **279**, 696–700 (1998).
- 626 4. Xu, D., Joglekar, A. P., Williams, A. L. & Hay, J. C. Subunit structure of a mammalian ER/Golgi SNARE
627 complex. *The Journal of biological chemistry* **275**, 39631–9 (2000).
- 628 5. Hay, J. C. *et al.* Localization, Dynamics, and Protein Interactions Reveal Distinct Roles for ER and Golgi
629 SNAREs. *The Journal of Cell Biology* **141**, 1489–1502 (1998).
- 630 6. Paek, I. *et al.* ERS-24, a Mammalian v-SNARE Implicated in Vesicle Traffic between the ER and the Golgi.
631 *The Journal of Cell Biology* **137**, 1017–1028 (1997).
- 632 7. Zhang, T. *et al.* Ykt6 forms a SNARE complex with syntaxin 5, GS28, and Bet1 and participates in a late
633 stage in endoplasmic reticulum-Golgi transport. *The Journal of biological chemistry* **276**, 27480–7 (2001).
- 634 8. Jahn, R. & Scheller, R. H. SNAREs — engines for membrane fusion. *Nature Reviews Molecular Cell Biology*
635 **7**, 631–631 (2006).
- 636 9. Banfield, D. K., Lewis, M. J. & Pelham, H. R. B. A SNARE-like protein required for traffic through the Golgi
637 complex. *Nature* **375**, 806–809 (1995).
- 638 10. Parlati, F. *et al.* Topological restriction of SNARE-dependent membrane fusion. *Nature* **407**, 194–198
639 (2000).
- 640 11. Parlati, F. *et al.* Distinct SNARE complexes mediating membrane fusion in Golgi transport based on
641 combinatorial specificity. *Proceedings of the National Academy of Sciences of the United States of America*
642 **99**, 5424–9 (2002).
- 643 12. Xu, Y., Martin, S., James, D. E. & Hong, W. GS15 Forms a SNARE Complex with Syntaxin 5, GS28, and Ykt6
644 and Is Implicated in Traffic in the Early Cisternae of the Golgi Apparatus. *MBoC* **13**, 3493–3507 (2002).
- 645 13. Linders, P. T., van der Horst, C., ter Beest, M. & van den Bogaart, G. Stx5-Mediated ER-Golgi Transport in
646 Mammals and Yeast. *Cells* **8**, 780 (2019).

- 647 14. Malsam, J. & Söllner, T. H. Organization of SNAREs within the Golgi stack. *Cold Spring Harbor perspectives*
648 *in biology* **3**, a005249–a005249 (2011).
- 649 15. Tai, G. *et al.* Participation of the Syntaxin 5/Ykt6/GS28/GS15 SNARE Complex in Transport from the
650 Early/Recycling Endosome to the Trans-Golgi Network. *MBoC* **15**, 4011–4022 (2004).
- 651 16. Dickinson, M. E. *et al.* High-throughput discovery of novel developmental phenotypes. *Nature* **537**, 508–
652 514 (2016).
- 653 17. Koscielny, G. *et al.* The International Mouse Phenotyping Consortium Web Portal, a unified point of access
654 for knockout mice and related phenotyping data. *Nucleic Acids Res* **42**, D802–D809 (2014).
- 655 18. Hui, N. *et al.* An isoform of the Golgi t-SNARE, syntaxin 5, with an endoplasmic reticulum retrieval signal.
656 *Molecular biology of the cell* **8**, 1777–87 (1997).
- 657 19. Gao, G. & Banfield, D. K. Multiple features within the syntaxin Sed5p mediate its Golgi localization. *Traffic*
658 **21**, 274–296 (2020).
- 659 20. Dominguez, M. *et al.* gp25L/emp24/p24 protein family members of the cis-Golgi network bind both COP I
660 and II coatomer. *The Journal of cell biology* **140**, 751–65 (1998).
- 661 21. Miyazaki, K. *et al.* Contribution of the long form of syntaxin 5 to the organization of the endoplasmic
662 reticulum. *Journal of Cell Science* **125**, 5658 LP – 5666 (2012).
- 663 22. Suga, K., Saito, A., Tomiyama, T., Mori, H. & Akagawa, K. The Syntaxin 5 Isoforms Syx5 and Syx5L have
664 Distinct Effects on the Processing of β -amyloid Precursor Protein. *The Journal of Biochemistry* **146**, 905–
665 915 (2009).
- 666 23. Avci, D. *et al.* The intramembrane protease SPP impacts morphology of the endoplasmic reticulum by
667 triggering degradation of morphogenic proteins. *J. Biol. Chem.* **294**, 2786–2800 (2019).
- 668 24. Hay, J. C., Hirling, H. & Scheller, R. H. Mammalian vesicle trafficking proteins of the endoplasmic reticulum
669 and Golgi apparatus. *J. Biol. Chem.* **271**, 5671–5679 (1996).
- 670 25. Shestakova, A., Suvorova, E., Pavliv, O., Khaidakova, G. & Lupashin, V. Interaction of the conserved
671 oligomeric Golgi complex with t-SNARE Syntaxin5a/Sed5 enhances intra-Golgi SNARE complex stability.
672 *The Journal of Cell Biology* **179**, 1179–1192 (2007).
- 673 26. Zhang, T. *et al.* The Mammalian Protein (rbet1) Homologous to Yeast Bet1p Is Primarily Associated with
674 the Pre-Golgi Intermediate Compartment and Is Involved in Vesicular Transport from the Endoplasmic
675 Reticulum to the Golgi Apparatus. *The Journal of Cell Biology* **139**, 1157–1168 (1997).

- 676 27. Mallard, F. *et al.* Early/recycling endosomes-to-TGN transport involves two SNARE complexes and a Rab6
677 isoform. *The Journal of Cell Biology* **156**, 653–664 (2002).
- 678 28. Dingjan, I. *et al.* Endosomal and Phagosomal SNAREs. *Physiological Reviews* **98**, 1465–1492 (2018).
- 679 29. Chiu, C.-F. *et al.* ZFPL1, a novel ring finger protein required for cis-Golgi integrity and efficient ER-to-Golgi
680 transport. *The EMBO journal* **27**, 934–47 (2008).
- 681 30. Jaiman, A. & Thattai, M. Algorithmic biosynthesis of eukaryotic glycans. *bioRxiv* 440792 (2018)
682 doi:10.1101/440792.
- 683 31. Glick, B. S. & Nakano, A. Membrane Traffic Within the Golgi Apparatus. *Annual Review of Cell and*
684 *Developmental Biology* **25**, 113–132 (2009).
- 685 32. Galea, G., Bexiga, M. G., Panarella, A., O’Neill, E. D. & Simpson, J. C. A high-content screening microscopy
686 approach to dissect the role of Rab proteins in Golgi-to-ER retrograde trafficking. *J Cell Sci* **128**, 2339–2349
687 (2015).
- 688 33. Boncompain, G. *et al.* Synchronization of secretory protein traffic in populations of cells. *Nature Methods*
689 **9**, 493–493 (2012).
- 690 34. Lippincott-Schwartz, J., Roberts, T. H. & Hirschberg, K. Secretory Protein Trafficking and Organelle
691 Dynamics in Living Cells. *Annual Review of Cell and Developmental Biology* **16**, 557–589 (2000).
- 692 35. Bindels, D. S. *et al.* mScarlet: a bright monomeric red fluorescent protein for cellular imaging. *Nature*
693 *Methods* **14**, 53–56 (2017).
- 694 36. Verboogen, D. R. J., González Mancha, N., ter Beest, M. & van den Bogaart, G. Fluorescence Lifetime
695 Imaging Microscopy reveals rerouting of SNARE trafficking driving dendritic cell activation. *eLife* **6**, (2017).
- 696 37. Griesbeck, O., Baird, G. S., Campbell, R. E., Zacharias, D. A. & Tsien, R. Y. Reducing the Environmental
697 Sensitivity of Yellow Fluorescent Protein MECHANISM AND APPLICATIONS. *J. Biol. Chem.* **276**, 29188–
698 29194 (2001).
- 699 38. Casey, J. R., Grinstein, S. & Orlowski, J. Sensors and regulators of intracellular pH. *Nature reviews.*
700 *Molecular cell biology* **11**, 50–61 (2010).
- 701 39. Antonin, W., Holroyd, C., Tikkanen, R., Höning, S. & Jahn, R. The R-SNARE Endobrevin/VAMP-8 Mediates
702 Homotypic Fusion of Early Endosomes and Late Endosomes. *MBoC* **11**, 3289–3298 (2000).
- 703 40. Bajno, L. *et al.* Focal Exocytosis of Vamp3-Containing Vesicles at Sites of Phagosome Formation. *J Cell Biol*
704 **149**, 697–706 (2000).

- 705 41. Hong, W. SNAREs and traffic. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research* **1744**, 120–
706 144 (2005).
- 707 42. Manderson, A. P., Kay, J. G., Hammond, L. A., Brown, D. L. & Stow, J. L. Subcompartments of the
708 macrophage recycling endosome direct the differential secretion of IL-6 and TNF α . *J Cell Biol* **178**, 57–69
709 (2007).
- 710 43. Murray, R. Z. A Role for the Phagosome in Cytokine Secretion. *Science* **310**, 1492–1495 (2005).
- 711 44. Amberger, J. S., Bocchini, C. A., Schiettecatte, F., Scott, A. F. & Hamosh, A. OMIM.org: Online Mendelian
712 Inheritance in Man (OMIM[®]), an online catalog of human genes and genetic disorders. *Nucleic Acids Res*
713 **43**, D789–D798 (2015).
- 714 45. Pedersen, A. G. & Nielsen, H. Neural network prediction of translation initiation sites in eukaryotes:
715 perspectives for EST and genome analysis. *Proc Int Conf Intell Syst Mol Biol* **5**, 226–233 (1997).
- 716 46. Kochetov, A. V. Alternative translation start sites and hidden coding potential of eukaryotic mRNAs.
717 *BioEssays* **30**, 683–691 (2008).
- 718 47. Kozak, M. Regulation of translation via mRNA structure in prokaryotes and eukaryotes. *Gene* **361**, 13–37
719 (2005).
- 720 48. Oka, T., Ungar, D., Hughson, F. M. & Krieger, M. The COG and COPI Complexes Interact to Control the
721 Abundance of GEARs, a Subset of Golgi Integral Membrane Proteins. *MBoC* **15**, 2423–2435 (2004).
- 722 49. Ohtsubo, K. & Marth, J. D. Glycosylation in Cellular Mechanisms of Health and Disease. *Cell* **126**, 855–867
723 (2006).
- 724 50. Freeze, H. H., Chong, J. X., Bamshad, M. J. & Ng, B. G. Solving Glycosylation Disorders: Fundamental
725 Approaches Reveal Complicated Pathways. *The American Journal of Human Genetics* **94**, 161–175 (2014).
- 726 51. Fisher, P. & Ungar, D. Bridging the Gap between Glycosylation and Vesicle Traffic. *Front. Cell Dev. Biol.* **4**,
727 (2016).
- 728 52. Blackburn, J. B., Kudlyk, T., Pokrovskaya, I. & Lupashin, V. V. More than just sugars: Conserved oligomeric
729 Golgi complex deficiency causes glycosylation-independent cellular defects. *Traffic* **19**, 463–480 (2018).
- 730 53. Foulquier, F. *et al.* Conserved oligomeric Golgi complex subunit 1 deficiency reveals a previously
731 uncharacterized congenital disorder of glycosylation type II. *PNAS* **103**, 3764–3769 (2006).
- 732 54. Foulquier, F. *et al.* A new inborn error of glycosylation due to a Cog8 deficiency reveals a critical role for
733 the Cog1–Cog8 interaction in COG complex formation. *Hum Mol Genet* **16**, 717–730 (2007).

- 734 55. Kranz, C. *et al.* COG8 deficiency causes new congenital disorder of glycosylation type IIh. *Hum Mol Genet*
735 **16**, 731–741 (2007).
- 736 56. Miller, V. J. & Ungar, D. Re‘COG’niton at the Golgi. *Traffic* **13**, 891–897 (2012).
- 737 57. Morava, E. *et al.* A common mutation in the COG7 gene with a consistent phenotype including
738 microcephaly, adducted thumbs, growth retardation, VSD and episodes of hyperthermia. *Eur J Hum Genet*
739 **15**, 638–645 (2007).
- 740 58. Ng, B. G. *et al.* Molecular and clinical characterization of a Moroccan Cog7 deficient patient. *Molecular*
741 *Genetics and Metabolism* **91**, 201–204 (2007).
- 742 59. Reynders, E. *et al.* Golgi function and dysfunction in the first COG4-deficient CDG type II patient. *Hum Mol*
743 *Genet* **18**, 3244–3256 (2009).
- 744 60. Wu, X. *et al.* Mutation of the COG complex subunit gene COG7 causes a lethal congenital disorder. *Nat*
745 *Med* **10**, 518–523 (2004).
- 746 61. Huchtagowder, V. *et al.* Loss-of-function mutations in ATP6V0A2 impair vesicular trafficking, tropoelastin
747 secretion and cell survival. *Hum Mol Genet* **18**, 2149–2165 (2009).
- 748 62. Jansen, J. C. *et al.* CCDC115 Deficiency Causes a Disorder of Golgi Homeostasis with Abnormal Protein
749 Glycosylation. *The American Journal of Human Genetics* **98**, 310–321 (2016).
- 750 63. Jansen, J. C. *et al.* TMEM199 Deficiency Is a Disorder of Golgi Homeostasis Characterized by Elevated
751 Aminotransferases, Alkaline Phosphatase, and Cholesterol and Abnormal Glycosylation. *The American*
752 *Journal of Human Genetics* **98**, 322–330 (2016).
- 753 64. Jansen, E. J. R. *et al.* ATP6AP1 deficiency causes an immunodeficiency with hepatopathy, cognitive
754 impairment and abnormal protein glycosylation. *Nature Communications* **7**, 11600–11600 (2016).
- 755 65. Foulquier, F. *et al.* TMEM165 Deficiency Causes a Congenital Disorder of Glycosylation. *The American*
756 *Journal of Human Genetics* **91**, 15–26 (2012).
- 757 66. Ashikov, A. *et al.* Integrating glycomics and genomics uncovers SLC10A7 as essential factor for bone
758 mineralization by regulating post-Golgi protein transport and glycosylation. *Hum Mol Genet* **27**, 3029–
759 3045 (2018).
- 760 67. Park, J. H. *et al.* SLC39A8 Deficiency: A Disorder of Manganese Transport and Glycosylation. *The American*
761 *Journal of Human Genetics* **97**, 894–903 (2015).

- 762 68. Witkos, T. M. *et al.* GORAB scaffolds COPI at the trans -Golgi for efficient enzyme recycling and correct
763 protein glycosylation. *Nat Commun* **10**, 1–18 (2019).
- 764 69. Zhong, W. Golgi during Development. *Cold Spring Harb Perspect Biol* **3**, (2011).
- 765 70. Zhao, H. Membrane Trafficking in Osteoblasts and Osteoclasts: New Avenues for Understanding and
766 Treating Skeletal Diseases. *Traffic* **13**, 1307–1314 (2012).
- 767 71. Wagner, T., Dieckmann, M., Jaeger, S., Weggen, S. & Pietrzik, C. U. Stx5 is a novel interactor of VLDL-R to
768 affect its intracellular trafficking and processing. *Experimental Cell Research* **319**, 1956–1972 (2013).
- 769 72. Morelle, W. & Michalski, J.-C. Analysis of protein glycosylation by mass spectrometry. *Nature Protocols* **2**,
770 1585–1602 (2007).
- 771 73. Scherpenzeel, M. van, Steenbergen, G., Morava, E., Wevers, R. A. & Lefeber, D. J. High-resolution mass
772 spectrometry glycoprofiling of intact transferrin for diagnosis and subtype identification in the congenital
773 disorders of glycosylation. *Translational Research* **166**, 639-649.e1 (2015).
- 774 74. Vissers, L. E. L. M. *et al.* A de novo paradigm for mental retardation. *Nature Genetics* **42**, 1109–1112
775 (2010).
- 776 75. Nikopoulos, K. *et al.* Next-Generation Sequencing of a 40 Mb Linkage Interval Reveals TSPAN12 Mutations
777 in Patients with Familial Exudative Vitreoretinopathy. *The American Journal of Human Genetics* **86**, 240–
778 247 (2010).
- 779 76. Ran, F. A. *et al.* Genome engineering using the CRISPR-Cas9 system. *Nature Protocols* **8**, 2281–2308
780 (2013).
- 781 77. Schägger, H. Tricine–SDS-PAGE. *Nat Protoc* **1**, 16–22 (2006).
- 782 78. Wickham, H. *ggplot2: Elegant Graphics for Data Analysis*. (Springer-Verlag New York, 2016).
783
784